Influence of verapamil on pharmacokinetics and transplacental transfer of ivermectin in sheep

Small Ruminant Research

Volumn 93, Issue 2-3, 2010, Pages 103-109

  Pérez, Rubén ^a   Palma, Cristina ^a   Núñez, María José ^a   Urrutia, Pedro ^a   Salazar, Aurelio ^a   Morales, Luis ^a   Vera, Daniela ^a   Cox, José ^a  

^a UNIVERSITY OF CONCEPCIÓN   (Chile)

Author keywords

Fetal sheep; Ivermectin; P glycoprotein; Pharmacokinetics; Verapamil

Indexed keywords

OVIS ARIES;

EID: 77956288902     PISSN: 09214488     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.smallrumres.2010.05.010     Document Type: Article

References (38)

1. Abbas A.E., Lester S.J., Connolly H. Pregnancy and the cardiovascular system. Int. J. Cardiol. 2005, 98:179-189.
2. Alvinerie M., Dupuy J., Eeckhoute C., Sutra J.F. Enhanced absorption of pour-on ivermectin formulation in rats by co-administration of the multidrug-resistant reversing agent verapamil. Parasitol. Res. 1999, 85:920-922.
3. Alvinerie M., Dupuy J., Kiki-Mvuoka S., Sutra J.F., Lespine A. Ketoconazole increases the plasma levels of ivermectin in sheep. Vet. Parasitol. 2008, 157:117-122.
4. Baylassac D., Authier N., Cayre A., Coudore F. Does inhibition of P-glycoprotein lead to drug-drug interactions?. Toxicol. Lett. 2005, 156:319-329.
5. Ballent M., Lifschitz A., Virkel G., Sallovitz J., Lanusse C. Modulation of the p-glycoprotein-mediated intestinal secretion of ivermectin: in vitro and in vivo assessments. Drug Metab. Dispos. 2006, 34:457-463.
6. Bansal T., Mishra G., Jaggi M., Khar R.K., Talegaonkar S. Effect of P-glycoprotein inhibitor, verapamil, on oral bioavailability and pharmacokinetics of irinotecan in rats. Eur. J. Pharm. Sci. 2009, 36:580-590.
7. Burkart C.N. Ivermectin: an assessment of its pharmacology, microbiology and safety. Vet. Hum. Toxicol. 2000, 42:30-35.
8. Campbell W.C., Benz G.W. Ivermectin: a review of efficacy and safety. J. Vet. Pharmacol. Ther. 1984, 7:1-16.
9. Ceckova-Novotna M., Pavek P., Stand F. P-glycoprotein in the placenta: expression, localization, regulation and function. Reprod. Toxicol. 2006, 22:400-410.
10. Chiu S-H.L., Lu A.Y.H. Metabolism and tissue residues. Ivermectin and Abamectin 1989, 131-143. Springer Verlag, New York, (Chapter 8). W.C. Campbell (Ed.).
11. Cotreau M.M., Warren S., Ryan J.L., Flekenstein L., Vanapalli S.R., Brown K.R., Rock D., Chen Ch-Y., Achwertschlag S. The antiparasitic moxidectin: safety, tolerability and pharmacokinetics in humans. J. Clin. Pharmacol. 2003, 43:1108-1115.
12. De Montigny P., Shim J.S.K., Pivinichny J.V. Liquid chromatographic determination of ivermectin in animal plasma with trifluoroacetic anhydride and N-methylimidazole as the derivatization reagent. J. Pharm. Biomed. Anal. 1990, 8:507-511.
13. Didier A.D., Loor F. Decreased biotolerability for ivermectin and cyclosporine A in mice exposed to potent P-glycoprotein inhibitors. Int. J. Cancer 1995, 63:263-267.
14. Flekenstein A. Specific pharmacology of calcium in myocardium, cardiac pacemaker and vascular smooth muscle. Ann. Rev. Pharmacol. Toxicol. 1977, 17:149-166.
15. Frederiksen M.C. Physiologic changes in pregnancy and their effect on drug disposition. Sem. Perinatol. 2001, 25:120-123.
16. Fromm M. Importance of P-glycoprotein at blood-tissue barriers. Trends Pharmacol. Sci. 2004, 26:423-429.
17. Hennessy D., Page S.W., Gottschall D.W. The behaviour of doramectin in the gastrointestinal tract, its secretion in bile and pharmacokinetic disposition in the peripheral circulation after oral and intravenous administration to sheep. J. Vet. Pharmacol. Ther. 2000, 23:203-213.
18. Hennesssy M., Spiers J.P. A primer on the mechanics of P-glycoprotein in the multidrug transporter. Pharmacol. Res. 2007, 55:1-15.
19. Laffont C.M., Toutain P., Alvinerie M., Bousquet-Mélou A. Intestinal secretion is a major route for parent ivermectin elimination in the rat. Drug Metab. Dispos. 2002, 30:626-630.
20. Lankas G.R., Gordon L.R. Toxicology. Ivermectin and Abamectin 1989, 82-112. Springer, New York. W.C. Campbell (Ed.).
21. Lankas G.R., Cartwright M.E., Umbenhauer D. P-glycoprotein deficiency in a subpopulation of CF-1 mice enhances avermectin-induced neurotoxicity. Toxicol. Appl. Pharmacol. 1997, 143:357-365.
22. Lankas G.R., Wise L.D., Cartwright M.E., Pippert T., Umbenhauer D.R. Placental p-glycoprotein deficiency enhances susceptibility to chemically induced birth defect in mice. Reprod. Toxicol. 1998, 12:457-463.
23. Lespine A., Martin S., Dupuy J., Roulet A., Pineau T., Orlowski S., Alvinerie M. Interaction of macrocyclic lactones with P-glycoprotein: structure-affinity relationship. Eur. J. Pharm. Sci. 2007, 30:84-94.
24. Leslie E.M., Deeley R.G., Cole S.P.C. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol. Appl. Pharmacol. 2005, 204:216-237.
25. Lifschitz A., Virkel G., Sallovitz I., Imperiale F., Pis A., Lanusse C. Loperamide-induced enhancement of moxidectin availability in cattle. J. Vet. Pharmacol. Ther. 2002, 25:111-120.
26. Molento M.B., Lifschitz A., Sallovitz J., Lanusse C., Prichard R. Influence of verapamil on the pharmacokinetics of the antiparasitic drugs ivermectin and moxidectin in sheep. Parasitol. Res. 2004, 92:121-127.
27. Nanovskaya T.N., Nekhayeva I.A., Hankins G.D.V., Ahmed M.S. Transfer of methadone across the dually perfused preterm human placental lobule. Am. J. Obstet. Gynecol. 2008, 198. 126.e1-12b.e4.
28. Nekayeva I.A., Nanovskaya T.N., Deshmukh S.V., Zharikova O.L., Hankins G.D.V., Ahmed M.S. Bidirectional transfer of methadone across human placenta. Biochem. Pharmacol. 2005, 69:187-197.
29. Perez R., Espinoza M., Riquelme R., Parer J.T., Llanos A.J. Arginine vasopressin mediates cardiovascular responses to hypoxemia in fetal sheep. Am. J. Physiol. 1989, 256:R1011-R1018.
30. Pérez R., Palma C., Nuñez M.J., Cox J. Pharmacokinetics of ivermectin after maternal or fetal intravenous administration in pregnant sheep. J. Vet. Pharmacol. Ther. 2008, 31:406-414.
31. Ramirez L.H., Munck J.-N., Zhao Z., Bognel C., Ricard M., Ardouin P., Rougier P., Gouyette A. Verapamil-reversing concentrations induce blood flow changes that could counteract in vivo the MDR-1-modulating effect. Cancer 1994, 74:810-816.
32. Schinkel A.H., Smitt J.J., van Tellingen O., Beijnen J.H., Wagenaar E., van Deemter L., Mol C.A., van der Valk M.A., Robamus-Mandag E.C., te Riele H.P., Berns A.J.M., Borst P. Disruption of the mouse mdr 1a P-glycoprotein gene lead to a deficiency in the blood-brain barrier and to increased sensitivity to drug. Cell 1994, 77:491-502.
33. Sikic B.I., Fisher G.A., Lum B.L., Halsey J., Beketic-Oreskovic L., Chen G. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein. Cancer Chemother. Pharmacol. 1997, 40(Suppl.):S13-S19.
34. Smit J.W., Huisman M.T., van Tellingen O., Wiltshire H.R., Schinkel A. Absence of pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure. J. Clin. Invest. 1999, 104:1441-1447.
35. Sun M., Kingdom J., Baczyk D., Lye S.J., Matthews S.G., Gibb W. Expression of the multidrug resistance P-glycoprotein, (ABCB1 glycoprotein) in the human placenta decrease with advancing gestation. Placenta 2006, 27:602-609.
36. Turner M.J., Schaeffer J.M. Mode of action of ivermectin. Ivermectin and Abamectin 1989, 73-78. Springer Verlag, New York. W.C. Campbell (Ed.).
37. Ushigone F., Takanaga H., Matsuo H., Yanai S., Tsukimori K., Nakano H., Uchiumi T., Nakamura T., Kuwano M., Ohtani H., Sawada Y. Human placental transport of vinblastine, vincristine, digoxin and progesterone: contribution of P-glycoprotein. Eur. J. Pharmacol. 2000, 408:1-10.
38. Wang R.B., Kuo C.L., Lien L.L., Lien E.J. Structure-activity relationship: analyses of P-glycoprotein substrates and inhibitors. J. Clin. Pharmacol. Ther. 2003, 28:203-228.